Buscador de ensayos clínicos de Fight CRC
NCT ID | Title | Fase | Date Added | Ubicación | Prior IO Allowed | CRC-directed | Status | Drogas | Etiquetas |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT05609370 |
TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer | Fase
Phase 1, Phase 2
|
Date Added 2022-11-08 |
Ubicación
Alaska, United States
Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Australia China Puerto Rico |
Prior IO Allowed No |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Bevacizumab, capecitabine, LBL-007, Tislelizumab |
Etiquetas
MSS/ MMRp
|
NCT ID NCT04085185 |
TitleEstudio de evaluación de la seguridad, tolerabilidad y eficacia inicial de IBI110 en sujetos con tumores malignos avanzados. | Fase
Fase 1
|
Date Added 2019-09-11 |
Ubicación
China
|
Prior IO Allowed Sí |
CRC-directed No |
Status
Reclutamiento
|
Drogas
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT04009681 |
TitleEstudio de evaluación de la seguridad y la actividad terapéutica de THOR-707 en sujetos adultos con tumores sólidos avanzados o metastásicos. | Fase
Fase 1
|
Date Added 2019-07-05 |
Ubicación
Arizona, United States
Colorado, United States Florida, United States Tennessee, United States Texas, United States Argentina Australia Chile Singapur España |
Prior IO Allowed No |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
anti-EGFR antibody, Checkpoint inhibitor, THOR-707 |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05653882 |
TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | Fase
Fase 1
|
Date Added 2022-12-16 |
Ubicación
California, United States
Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States |
Prior IO Allowed Sí |
CRC-directed No |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05491317 |
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | Fase
Phase 1, Phase 2
|
Date Added 2022-08-08 |
Ubicación
Francia
|
Prior IO Allowed Sí |
CRC-directed No |
Status
Activo, no recluta
|
Drogas
Pembrolizumab |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06513221 |
TitleA Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab | Fase |
Date Added 2024-07-22 |
Ubicación |
Prior IO Allowed No |
CRC-directed Sí |
Status |
Drogas |
Etiquetas
MSS/ MMRp
|
NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | Fase
Fase 2
|
Date Added 2019-06-10 |
Ubicación
Reino Unido
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Activo, no recluta
|
Drogas
Nivolumab, Opdivo |
Etiquetas
MSS/ MMRp
|
NCT ID NCT05205330 |
TitleUn estudio de fase Ib/IIa de CR6086 en combinación con balstilimab en pacientes con cáncer colorrectal metastásico pMMR-MSS | Fase
Fase 2
|
Date Added 2022-01-25 |
Ubicación
Italia
|
Prior IO Allowed No |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
AGEN2034, Balstilimab, CR6086 |
Etiquetas
MSS/ MMRp
|
NCT ID NCT04550897 |
TitleA Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients | Fase
Fase 1
|
Date Added 2020-09-16 |
Ubicación
Noruega
|
Prior IO Allowed Sí |
CRC-directed Sí |
Status
Reclutamiento
|
Drogas
BM7PE |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT06508307 |
TitleA Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | Fase
Fase 1
|
Date Added 2024-07-18 |
Ubicación
China
|
Prior IO Allowed Sí |
CRC-directed No |
Status
Reclutamiento
|
Drogas |
Etiquetas
MSI-H/ MMRd, MSS/ MMRp
|